Retatrutide
Triple agonist of the GIP, GLP-1 and Glucagon receptors. The addition of Glucagon agonism increases energy expenditure (calorie burning) at rest, as well as suppressing appetite.
- Extreme weight loss (up to 24% in early stages)
- Increased basal metabolism
- Liver improvement (fatty liver)
- Glycaemic controlExtreme weight loss (up to 24% in early stages)
- Glycaemic control
- Tachycardia (increased heart rate), nausea.
Retatrutide is an innovative peptide that acts as a triple agonist at the GLP-1, GIP and Glucagon receptors, representing the current pinnacle of metabolic pharmacology for the treatment of obesity.
READ MORE
What it is (in plain language)
- It's the 'super-Ozempic'. While previous drugs focussed on one or two satiety signals, Retatrutide focuses on three. It reduces appetite (GLP-1), improves fat efficiency (GIP) and directly increases calorie burning by the liver (Glucagon). In studies, it has been shown to be the most potent compound ever created for weight loss.
Why do you appear online so much
- It has become the main topic of all recent endocrinology conferences due to weight loss results that rival bariatric surgery. It is the greatest hope for those with extreme resistance to weight loss.
How it is framed today (pragmatic view)
- 1) Evidence: Phase II clinical trials with unprecedented results in the history of medicine. 2) Objective: Treatment of morbid obesity and aggressive type 2 diabetes. 3) Risk: Requires constant medical supervision due to the profound impact on metabolism and heart rate.
How to use this form
- Compare Retatrutide with Semaglutide in our efficacy table to understand the differences in potency.
- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Metabolic
- Route: Injectable
- Tags: Injectable|Fat Loss|Experimental
- Half-life: ~6 Days
- Start: 24-48 hours
- Duration: 7 days
- Mechanism (high level)
Triple agonist of the GIP, GLP-1 and Glucagon receptors. The addition of Glucagon agonism increases energy expenditure (calorie burning) at rest, as well as suppressing appetite.
- Evidence (what the literature covers)
RESEARCH RANGE (Clinical Phase 2/3, Non-prescriptive):
Still in trials. Experimental doses up to 12mg.
Level of Evidence: A (promising Phase 2 trials).
- Safety and harm-reduction (non-prescriptive)
Risks: Tachycardia (increased heart rate), nausea.
Interactions: Unknown.
- References (anchors)
- Jastreboff, A. M. (2023) - Retatrutide for obesity phase 2 trial - https://doi.org/10.1056/NEJMoa2301972 | PubMed:37366315
- Mueller, T. D. (2023) - Retatrutide (LY3437943) triple agonist - https://doi.org/10.1016/S0140-6736(23)01053-X | PubMed:37366314
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL